Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.56 Analyst target: $6.60 Upside: 1077.94%
Aldeyra Therapeutics, Inc., a biotechnology company, develops and markets drugs for immune-mediated systemic and eye diseases. The company is headquartered in Lexington, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.